Wedbush Reiterates Outperform on ORIC Pharmaceuticals, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has reiterated an Outperform rating for ORIC Pharmaceuticals, maintaining a price target of $20.
September 10, 2024 | 12:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst David Nierengarten has reiterated an Outperform rating for ORIC Pharmaceuticals, maintaining a price target of $20. This suggests confidence in ORIC's future performance.
The reiteration of an Outperform rating and a $20 price target by a reputable analyst suggests positive sentiment and potential upside for ORIC Pharmaceuticals. This could lead to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100